BRISTOL MYERS SQUIBB

Bristol Myers Squibb agreed to pay $350 million upfront to Philochem for worldwide rights to OncoACP3, an experimental radiopharmaceutical targeting the ACP3 protein for prostate cancer diagnosis and treatment.

RayzeBio, a Bristol Myers Squibb subsidiary, has licensed exclusive worldwide rights to OncoACP3, a novel radiopharmaceutical targeting prostate cancer, from Philochem AG for up to $1.35 billion.

The NRG-BR003 phase 3 trial found that adding carboplatin to standard paclitaxel and doxorubicin/cyclophosphamide chemotherapy did not provide statistically significant improvements in survival outcomes for triple-negative breast cancer patients.

Nkarta has appointed Shawn Rose, M.D. Ph.D., as Chief Medical Officer and Head of R&D, effective June 23, 2025, replacing David R. Shook who is returning to oncology.

Denovo Biopharma has established a neuroscience Scientific Advisory Board chaired by Dr. Charles B. Nemeroff to guide development of its Phase 3-ready biomarker-guided depression therapy DB104.

Researchers analyzed genetic material from 1,225 metastatic melanoma patients and identified that those with mitochondrial haplogroup T (HG-T) were 3.46 times less likely to respond to checkpoint inhibitor therapy.

Mediar Therapeutics has dosed the first patient in its Phase 2 WISPer trial evaluating MTX-463, a first-in-class anti-WISP1 antibody for idiopathic pulmonary fibrosis treatment.

The European Investment Bank has committed €30 million in venture debt financing to French biotech TreeFrog Therapeutics to advance their regenerative cell therapy program for Parkinson's disease.

Redwire Corporation has secured a contract from Aspera Biomedicines to conduct space-based research on rebecsinib, a small-molecule ADAR1 inhibitor that recently received FDA approval for first-in-human trials.

Bristol Myers Squibb will pay BioNTech $1.5 billion upfront plus $2 billion in anniversary payments through 2028 for a 50% partnership in BNT327, a bispecific antibody targeting both PD-L1 and VEGF proteins.